Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Leuk Res. 2012 May;36(5):570-4. doi: 10.1016/j.leukres.2011.10.023. Epub 2011 Dec 9.
Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain salicylate levels known to inhibit NF-κB in vitro in 11 patients with MDS or AML taking sodium salicylate. Most patients achieved the target blood salicylate level (20-30mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (n=4) and ototoxicity (n=4). One patient had grade 3/4 elevations in AST/ALT. This study suggests that sodium salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity or hepatotoxicity.
柳氮磺胺吡啶是一种廉价、易得的抗炎药，可抑制体外 NF-κB。我们研究了 11 例 MDS 或 AML 患者服用柳氮磺胺吡啶后，是否可以安全地达到并维持体外抑制 NF-κB 的水杨酸盐水平。大多数患者实现了目标血水杨酸盐水平（20-30mg/dL），具有可接受的毒性，包括可逆的 1/2 级肝转氨酶升高（n=4）和耳毒性（n=4）。1 例患者 AST/ALT 升高至 3/4 级。本研究表明，柳氮磺胺吡啶可能与不伴有明显耳毒性或肝毒性的常规化疗方案安全联合。
